Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Consolidated Edison, Inc. (ED) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance

Consolidated Edison, Inc.Trade
IDEXX Laboratories, Inc.Trade

Price performance (Past 24H)

Key statistics

Consolidated Edison, Inc. vs IDEXX Laboratories, Inc. — how do they compare? Consolidated Edison, Inc. trades at $107.3 (market cap $39.76B), while IDEXX Laboratories, Inc. trades at $572.77 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Consolidated Edison, Inc. pays a 3.27% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.

EDIDXX
Market Cap
$39.76B$46.22B
Sector
UtilitiesHealth
52-Week High
$115.46$766.68
52-Week Low
$95.37$526.44
Enterprise Value
$66.61B$47.12B
Dividend Yield
3.27%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Consolidated Edison, Inc.

Consolidated Edison (ED) trades at $107.33, up 0.97% on the day, slightly above the consensus price target of $103.25. The stock shows a mixed technical picture with bearish moving averages but neutral oscillators, while fundamentals are stable with a P/E of 17.68, net income margin of 12.53%, and consistent dividends. Recent Q2 2026 earnings beat estimates with EPS of $0.83 versus $0.756 expected, though Q1 2026 missed expectations.

Outlook is cautious due to analyst sentiment favoring Hold (62.96%) and bearish technical signals, but the utility's regulated operations and mid-8% rate base growth support steady returns. Risks include high debt levels and interest rate sensitivity, while opportunities lie in grid upgrades for AI-driven power demand. The stock offers a defensive profile with a reliable dividend yield.

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.

Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Consolidated Edison, Inc.

Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.

Read more on ED

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX